Publications by authors named "C W Deal"
At the 2023 Global Vaccine and Immunization Research Forum (GVIRF), researchers from around the world gathered in the Republic of Korea to discuss advances and opportunities in vaccines and immunization. Many stakeholders are applying the lessons of Covid-19 to future emergencies, by advancing early-stage development of prototype vaccines to accelerate response to the next emerging infectious disease, and by building regional vaccine research, development, and manufacturing capacity to speed equitable access to vaccines in the next emergency. Recent vaccine licensures include: respiratory syncytial virus vaccines, both for the elderly and to protect infants through maternal immunization; a new dengue virus vaccine; and licensure of Covid-19 vaccines previously marketed under emergency use authorizations.
View Article and Find Full Text PDFNew, first-in-class oral antibiotics like zoliflodacin, developed in a public-private partnership, require an optimal introduction strategy while ensuring antibiotic stewardship. Zoliflodacin, given as a single dose for uncomplicated urogenital gonorrhoea, recently demonstrated non-inferiority to ceftriaxone plus azithromycin and safety in a phase 3 randomised controlled trial. Following regulatory approval, zoliflodacin could improve sexually transmitted infection (STI) management and help address the threat of untreatable gonorrhoea, as levels of resistance to current first-line treatments increase.
View Article and Find Full Text PDFContext: Several long-acting growth hormone (LAGH) therapies have recently become available, but guidance on their usage in children with growth hormone (GH) deficiency is limited.
Methods: International experts in pediatric endocrinology were invited to join a consensus group based on their expertise in treating children with daily GH and LAGH. The group comprised 11 experts from 10 countries across the world.
Article Synopsis
- The recent surge in syphilis cases in the U.S. poses significant public health challenges, particularly due to intermittent shortages of benzathine penicillin, the primary treatment for the infection.
- Experts from the National Institute of Allergy and Infectious Diseases (NIAID) gathered in February 2024 to explore alternative therapies for treating syphilis, focusing on existing antibiotics with good safety profiles.
- Workshop discussions highlighted difficulties in designing clinical trials for alternative treatments due to penicillin's high effectiveness and varied patient demographics and health conditions.
Article Synopsis
- Weekly injections for treating growth deficiency in children are just as effective as daily injections, showing similar growth rates.
- The safety of weekly injections is comparable to daily injections, indicating no significant risk differences.
- It's important to note that treatment decisions should consider all evidence, not just one study, and approval for the drug may vary by country.